Coverage
-
October 01, 2015
Eisai Inc. lost its bid to require the U.S. Food and Drug Administration to extend the market exclusivity periods for two of its drugs when a Washington, D.C., federal judge found Wednesday he had to defer to the agency's own interpretation of its standards for drug marketing.
2 other articles on this case.
View all »